Biased assessment of blinding in a randomized placebo-controlled trial of oral methotrexate in chronic progressive multiple sclerosis
- PMID: 7486877
- DOI: 10.1002/ana.410380521
Biased assessment of blinding in a randomized placebo-controlled trial of oral methotrexate in chronic progressive multiple sclerosis
Comment on
-
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.Ann Neurol. 1995 Jan;37(1):30-40. doi: 10.1002/ana.410370108. Ann Neurol. 1995. PMID: 7818255 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources